Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cost of Revenue (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Cost of Revenue for 4 consecutive years, with $49000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue fell 27.94% to $49000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $197000.0, a 2.07% increase, with the full-year FY2024 number at $204000.0, up 9.68% from a year prior.
  • Cost of Revenue was $49000.0 for Q3 2025 at Orchestra BioMed Holdings, up from $46000.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $68000.0 in Q3 2024 to a low of $34000.0 in Q1 2024.
  • A 4-year average of $49333.3 and a median of $47000.0 in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 65.85% in 2024, then dropped 27.94% in 2025.
  • Orchestra BioMed Holdings' Cost of Revenue stood at $53000.0 in 2022, then dropped by 11.32% to $47000.0 in 2023, then rose by 23.4% to $58000.0 in 2024, then dropped by 15.52% to $49000.0 in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Cost of Revenue are $49000.0 (Q3 2025), $46000.0 (Q2 2025), and $44000.0 (Q1 2025).